A total of 52.0% of the patients had a CPS-EG score of≤3, whereas 48.0% had a score of>3. The rate of patients who achieved pCR was 29.7% (n=44). CPS-EG score (HR: 2.331; 95%CI; 1.179–4.608;p=0.015), pCR (HR: 0.348; 95%CI; 0.144–0.844;p=0.019), pre-treatment mKi...
CPS+EG score was significantly associated with cause-specific survival (p<0.001) with an AUC of 0.69 (95% CI 0.62-0.77) at 5years. This was higher than the AUC of 0.63 (95% CI 0.56-0.70) for AJCC PS (p=0.10).#This study validates the CPS+EG staging system using Nottingham grade ...
Come summer,Tartu’scultural scene becomes even more lively than usual, with festivals and performances celebrating everything from street art to jazz. Take a sunny walk over the Angel’s and the Devil’s bridge to explore the ...
CPS+EG score was unable to identify non-pCR pts with a sufficiently good prognosis, to avoid post neoadjuvant therapy. The best prognostic CPS+EG groups (score 1/2) in non-pCR pts had a 5-year DFS of 77.5% and 74.4%, respectively (n=362; 37.2%). CPS+EG identified a small group ...
CPS plus EG scoreHormone-receptor positiveHER2 negativeBreast cancerPrognosisNeoadjuvant chemotherapyPathologic complete responseBackground: Pathologic complete response after neoadjuvant chemotherapy (NACT) correlates with overall survival (OS) in primary breast cancer. A recently described staging system based ...
CPS plus EG scoreHormone-receptor positiveHER2 negativeBreast cancerPrognosisNeoadjuvant chemotherapyPathologic complete responseBackground: Pathologic complete response after neoadjuvant chemotherapy (NACT) correlates with overall survival (OS) in primary breast cancer. A recently described staging system based ...
CPS+EG did not discriminate prognosis within the two best prognostic groups (score 1 and 2; n=362; 37.2%). In contrast, pCR status added prognostic information beyond CPS+EG. Patients with a CPS+EG score of 3 had a 5-year DFS rate of 64% overall, but those with pCR had a 5-year...
The CPS+EG, Neo-Bioscore, and modified Neo-Bioscore could all stratify the DFS, DSS and OS (all P<0.001). While in the same stratum of Neo-Bioscore score 2 and 3, the HER2-positive patients without trastuzumab therapy had much poorer DSS (P=0.013 and P values <0.01, respectively) ...